Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + simvastatin
- Development stage
- Phase 4
- Lead developer
- Merck KGaA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of two medications used to treat metabolic disorders. Metformin is an oral antidiabetic medication that enhances insulin sensitivity and regulates lipid metabolism, while simvastatin is a statin that lowers cholesterol levels. The combination has shown superior efficacy compared to metformin alone in treating polycystic ovary syndrome (PCOS), with advantages in improving sex hormones, blood lipids, and blood sugar levels.
- Other names
- metformin and simvastatin combinationneoadjuvant metformin and simvastatinMetformin and Simvastatin in Invasive Bladder Cancer
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AMPK (Adenosine monophosphate–activated protein kinase)
Beyond the preview
Go deeper on metformin + simvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + simvastatin.